Chemed Reports Fourth-Quarter 2018 Results
Consolidated operating results:
-
Revenue increased 6.8% to
$458 million -
GAAP Diluted Earnings-per-Share (EPS) of
$3.26 -
Adjusted Diluted EPS of
$3.35 , an increase of 44.4%
VITAS segment operating results:
-
Net Patient Revenue of
$307 million , an increase of 5.0% - Average Daily Census (ADC) of 18,149, an increase of 7.3%
- Admissions of 16,579, essentially equal to prior year
-
Net Income, excluding special items, of
$40.2 million , an increase of 40.7% -
Adjusted EBITDA, excluding cap, of
$55.5 million , an increase of 11.2%
Roto-Rooter segment operating results:
-
Revenue of
$151 million , an increase of 10.6% -
Net Income, including special items, of
$26.2 million , an increase of 46.9% -
Adjusted EBITDA of
$36.1 million , an increase of 16.3% - Adjusted EBITDA margin of 24.0%, an increase of 118-basis points
Effective
This resulted in the reclassification of net room and board expenses
associated with certain patients residing in nursing homes to be
reclassified from cost of services to revenue, effectively reducing
VITAS’ fourth-quarter 2018 revenue and cost of sales by
The discussion and analysis of operating results in this fourth-quarter 2018 earnings release narrative does reclassify the fourth-quarter 2017 net room and board and estimated uncollectable receivables to facilitate analysis of operating results in a format consistent with the 2018 revenue recognition accounting standard.
VITAS
VITAS net revenue was
In the fourth quarter of 2018, VITAS accrued
Of VITAS’ 30
Average revenue per patient per day in the quarter was
The fourth quarter of 2018 gross margin, excluding Medicare Cap, was 24.0%, which is a 13-basis point increase when compared to the fourth quarter of 2017.
Selling, general and administrative expense was
Roto-Rooter
Roto-Rooter generated quarterly revenue of
Commercial drain cleaning revenue increased 11.6%, commercial plumbing and excavation increased 12.5% and commercial water restoration increased 12.4%. Overall, commercial revenue increased 12.0%.
Residential drain cleaning increased 9.4%, plumbing and excavation increased 14.2% and residential water restoration increased 9.3%. Aggregate residential sales increased 11.4%.
Roto-Rooter’s gross margin in the quarter was 48.8%, a 6-basis point
decline when compared to the fourth quarter of 2017. Adjusted EBITDA in
the fourth quarter of 2018 totaled
Chemed Consolidated
As of
In
During the quarter, the Company repurchased 130,524 shares of
Guidance for 2019
Revenue growth for VITAS in 2019, prior to Medicare Cap, is estimated to
be in the range of 5.5% to 6.0%. Admissions are estimated to expand
approximately 3.0% to 4.0% and Average Daily Census in 2019 is estimated
to expand approximately 4.0% to 5.0%. Full-year Adjusted EBITDA margin,
prior to Medicare Cap, is estimated to be 15.9%. We are currently
estimating
Roto-Rooter is forecasted to achieve full-year 2019 revenue growth of 9.0% to 10.0%. This revenue estimate is based upon increased job pricing of approximately 2%, continued growth in core plumbing and drain cleaning services as well as continued but slowing revenue growth from water restoration services. Roto-Rooter’s Adjusted EBITDA margin for 2019 is estimated at 23.7%.
Based upon the above, full-year 2019 adjusted earnings per diluted
share, excluding non-cash expense for stock options, tax benefits from
stock options, costs related to litigation, and other discrete items, is
estimated to be in the range of
Conference Call
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (855) 859-2056 for U.S. and Canadian callers and +1 (404) 537-3406 for international callers and will be available for one week following the live call. The replay Conference ID is 8283536. An archived webcast will also be available at www.chemed.com.
This press release contains information about Chemed’s EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS, which are not measures derived in
accordance with GAAP and which exclude components that are important to
understanding Chemed’s financial performance. In reporting its operating
results,
Forward-Looking Statements
Certain statements contained in this press release and the accompanying
tables are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "hope," "anticipate," "plan" and similar expressions identify
forward-looking statements, which speak only as of the date the
statement was made.
These risks and uncertainties arise from, among other things, possible
changes in regulations governing the hospice care or plumbing and drain
cleaning industries; periodic changes in reimbursement levels and
procedures under
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||||
CONSOLIDATED STATEMENT OF INCOME | |||||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | |||||||||||||||||||||||||
Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||||||||||
Service revenues and sales | $ | 457,507 | $ | 428,357 | $ | 1,782,648 | $ | 1,666,724 | |||||||||||||||||
Cost of services provided and goods sold | 313,054 | 291,493 | 1,228,644 | 1,150,532 | |||||||||||||||||||||
Selling, general and administrative expenses (aa) | 65,735 | 71,621 | 270,209 | 276,652 | |||||||||||||||||||||
Depreciation | 9,822 | 8,943 | 38,464 | 35,488 | |||||||||||||||||||||
Amortization | 303 | 26 | 399 | 137 | |||||||||||||||||||||
Other operating (income)/expenses | 1,212 | (258 | ) | 1,300 | 90,880 | ||||||||||||||||||||
Total costs and expenses | 390,126 | 371,825 | 1,539,016 | 1,553,689 | |||||||||||||||||||||
Income from operations | 67,381 | 56,532 | 243,632 | 113,035 | |||||||||||||||||||||
Interest expense | (1,177 | ) | (1,108 | ) | (4,990 | ) | (4,272 | ) | |||||||||||||||||
Other income--net (bb) | (3,398 | ) | 2,715 | 958 | 8,154 | ||||||||||||||||||||
Income before income taxes | 62,806 | 58,139 | 239,600 | 116,917 | |||||||||||||||||||||
Income taxes | (8,478 | ) | (3,587 | ) | (34,056 | ) | (18,740 | ) | |||||||||||||||||
Net income | $ | 54,328 | $ | 54,552 | $ | 205,544 | $ | 98,177 | |||||||||||||||||
Earnings Per Share | |||||||||||||||||||||||||
Net income | $ | 3.39 | $ | 3.40 | $ | 12.80 | $ | 6.11 | |||||||||||||||||
Average number of shares outstanding | 16,026 | 16,026 | 16,059 | 16,057 | |||||||||||||||||||||
Diluted Earnings Per Share | |||||||||||||||||||||||||
Net income | $ | 3.26 | $ | 3.25 | $ | 12.23 | $ | 5.86 | |||||||||||||||||
Average number of shares outstanding | 16,670 | 16,776 | 16,803 | 16,742 | |||||||||||||||||||||
(aa) | Selling, general and administrative ("SG&A") expenses comprise (in thousands): | ||||||||||||||||||||||||
Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||||||||||
SG&A expenses before long-term incentive compensation, expenses related to the OIG investigation and the impact of market value adjustments related to deferred compensation plans |
$ | 67,034 | $ | 66,821 | $ | 263,304 | $ | 258,034 | |||||||||||||||||
Market value adjustments related to deferred compensation plans |
(3,541 | ) | 2,811 | 287 | 8,430 | ||||||||||||||||||||
Long-term incentive compensation | 2,242 | 1,973 | 6,618 | 4,994 | |||||||||||||||||||||
Expenses related to the OIG investigation | - | 16 | - | 5,194 | |||||||||||||||||||||
Total SG&A expenses | $ | 65,735 | $ | 71,621 | $ | 270,209 | $ | 276,652 | |||||||||||||||||
(bb) | Other income--net comprises (in thousands): | ||||||||||||||||||||||||
Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||||||||||
|
|||||||||||||||||||||||||
Market value adjustments related to deferred compensation plans |
$ | (3,541 | ) | $ | 2,811 | $ | 287 | $ | 8,430 | ||||||||||||||||
Interest income | 143 | 131 | 671 | 427 | |||||||||||||||||||||
Other | - | (227 | ) | - | (703 | ) | |||||||||||||||||||
Total other income--net | $ | (3,398 | ) | $ | 2,715 | $ | 958 | $ | 8,154 | ||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||
CONSOLIDATED BALANCE SHEET | |||||||||||||||||||
(in thousands, except per share data)(unaudited) | |||||||||||||||||||
December 31, | |||||||||||||||||||
2018 | 2017 | ||||||||||||||||||
Assets | |||||||||||||||||||
Current assets | |||||||||||||||||||
Cash and cash equivalents | $ | 4,831 | $ | 11,121 | |||||||||||||||
Accounts receivable less allowances | 119,504 | 113,651 | |||||||||||||||||
Inventories | 5,705 | 5,334 | |||||||||||||||||
Prepaid income taxes | 10,646 | 29,848 | |||||||||||||||||
Prepaid expenses | 19,154 | 16,092 | |||||||||||||||||
Total current assets | 159,840 | 176,046 | |||||||||||||||||
Investments of deferred compensation plans held in trust | 65,624 | 62,067 | |||||||||||||||||
Properties and equipment, at cost less accumulated depreciation | 162,033 | 143,034 | |||||||||||||||||
Identifiable intangible assets less accumulated amortization | 68,253 | 54,865 | |||||||||||||||||
Goodwill | 510,570 | 476,887 | |||||||||||||||||
Other assets | 9,209 | 7,127 | |||||||||||||||||
Total Assets | $ | 975,529 | $ | 920,026 | |||||||||||||||
Liabilities | |||||||||||||||||||
Current liabilities | |||||||||||||||||||
Accounts payable | $ | 50,150 | $ | 48,372 | |||||||||||||||
Current portion of long-term debt | - | 10,000 | |||||||||||||||||
Accrued insurance | 46,095 | 46,968 | |||||||||||||||||
Accrued compensation | 63,329 | 62,933 | |||||||||||||||||
Accrued legal | 1,857 | 1,786 | |||||||||||||||||
Other current liabilities | 30,239 | 23,463 | |||||||||||||||||
Total current liabilities | 191,670 | 193,522 | |||||||||||||||||
Deferred income taxes | 21,598 | 16,640 | |||||||||||||||||
Long-term debt | 89,200 | 91,200 | |||||||||||||||||
Deferred compensation liabilities | 64,616 | 61,800 | |||||||||||||||||
Other liabilities | 17,111 | 16,510 | |||||||||||||||||
Total Liabilities | 384,195 | 379,672 | |||||||||||||||||
Stockholders' Equity | |||||||||||||||||||
Capital stock | 35,311 | 34,732 | |||||||||||||||||
Paid-in capital | 774,358 | 695,797 | |||||||||||||||||
Retained earnings | 1,225,617 | 1,038,955 | |||||||||||||||||
Treasury stock, at cost | (1,446,296 | ) | (1,231,332 | ) | |||||||||||||||
Deferred compensation payable in Company stock | 2,344 | 2,202 | |||||||||||||||||
Total Stockholders' Equity | 591,334 | 540,354 | |||||||||||||||||
Total Liabilities and Stockholders' Equity | $ | 975,529 | $ | 920,026 | |||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||
CONSOLIDATED STATEMENT OF CASH FLOWS | |||||||||||||||||
(in thousands)(unaudited) | |||||||||||||||||
For the Years Ended December 31, | |||||||||||||||||
2018 | 2017 | ||||||||||||||||
Cash Flows from Operating Activities | |||||||||||||||||
Net income | $ | 205,544 | $ | 98,177 | |||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
|||||||||||||||||
Depreciation and amortization | 38,863 | 35,625 | |||||||||||||||
Stock option expense | 12,611 | 10,485 | |||||||||||||||
Noncash long-term incentive compensation | 5,405 | 3,774 | |||||||||||||||
Benefit for deferred income taxes | 5,187 | 2,407 | |||||||||||||||
Noncash directors' compensation | 766 | 766 | |||||||||||||||
Amortization of restricted stock awards | 446 | 1,231 | |||||||||||||||
Amortization of debt issuance costs | 441 | 516 | |||||||||||||||
Provision for uncollectible accounts receivable | - | 17,306 | |||||||||||||||
Loss on sale of transportation equipment | - | 5,266 | |||||||||||||||
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: |
|||||||||||||||||
(Increase)/decrease in accounts receivable | (5,570 | ) | 1,072 | ||||||||||||||
(Increase)/decrease in inventories | (351 | ) | 421 | ||||||||||||||
Increase in prepaid expenses | (2,665 | ) | (2,987 | ) | |||||||||||||
Decrease in accounts payable and other current liabilities |
8,935 | 12,890 | |||||||||||||||
Change in current income taxes | 18,898 | (26,104 | ) | ||||||||||||||
Increase in other assets | (5,544 | ) | (8,330 | ) | |||||||||||||
Increase in other liabilities | 3,451 | 8,561 | |||||||||||||||
Other sources | 721 | 1,419 | |||||||||||||||
Net cash provided by operating activities | 287,138 | 162,495 | |||||||||||||||
Cash Flows from Investing Activities | |||||||||||||||||
Capital expenditures | (52,872 | ) | (64,300 | ) | |||||||||||||
Business combinations, net of cash acquired | (53,177 | ) | (4,725 | ) | |||||||||||||
Other sources | 824 | 1,417 | |||||||||||||||
Net cash used by investing activities | (105,225 | ) | (67,608 | ) | |||||||||||||
Cash Flows from Financing Activities | |||||||||||||||||
Proceeds from revolving line of credit | 469,550 | 212,350 | |||||||||||||||
Payments on revolving line of credit | (406,550 | ) | (211,150 | ) | |||||||||||||
Purchases of treasury stock | (158,884 | ) | (94,640 | ) | |||||||||||||
Payments on other long-term debt | (75,000 | ) | (8,750 | ) | |||||||||||||
Proceeds from exercise of stock options | 32,412 | 27,092 | |||||||||||||||
Capital stock surrendered to pay taxes on stock-based compensation | (27,548 | ) | (14,223 | ) | |||||||||||||
Dividends paid | (18,662 | ) | (17,371 | ) | |||||||||||||
Change in cash overdrafts payable | (1,531 | ) | 6,700 | ||||||||||||||
Debt issuance costs | (1,052 | ) | - | ||||||||||||||
Other (uses)/sources | (938 | ) | 916 | ||||||||||||||
Net cash used by financing activities | (188,203 | ) | (99,076 | ) | |||||||||||||
Decrease in Cash and Cash Equivalents | (6,290 | ) | (4,189 | ) | |||||||||||||
Cash and cash equivalents at beginning of year | 11,121 | 15,310 | |||||||||||||||
Cash and cash equivalents at end of period | $ | 4,831 | $ | 11,121 | |||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | |||||||||||||||||||||
FOR THE THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017 | |||||||||||||||||||||
(in thousands)(unaudited) |
|||||||||||||||||||||
Chemed | |||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||
2018 | |||||||||||||||||||||
Service revenues and sales | $ | 306,985 | $ | 150,522 | $ | - | $ | 457,507 | |||||||||||||
Cost of services provided and goods sold | 235,971 | 77,083 | - | 313,054 | |||||||||||||||||
Selling, general and administrative expenses (a) | 19,363 | 37,563 | 8,809 | 65,735 | |||||||||||||||||
Depreciation | 4,935 | 4,847 | 40 | 9,822 | |||||||||||||||||
Amortization | 12 | 291 | - | 303 | |||||||||||||||||
Other operating expense | 1,114 | 98 | - | 1,212 | |||||||||||||||||
Total costs and expenses | 261,395 | 119,882 | 8,849 | 390,126 | |||||||||||||||||
Income/(loss) from operations | 45,590 | 30,640 | (8,849 | ) | 67,381 | ||||||||||||||||
Interest expense | (22 | ) | (64 | ) | (1,091 | ) | (1,177 | ) | |||||||||||||
Intercompany interest income/(expense) | 3,308 | 1,678 | (4,986 | ) | - | ||||||||||||||||
Other income—net | 110 | 32 | (3,540 | ) | (3,398 | ) | |||||||||||||||
Income/(loss) before income taxes | 48,986 | 32,286 | (18,466 | ) | 62,806 | ||||||||||||||||
Income taxes (a) | (9,860 | ) | (6,375 | ) | 7,757 | (8,478 | ) | ||||||||||||||
Net income/(loss) | $ | 39,126 | $ | 25,911 | $ | (10,709 | ) | $ | 54,328 | ||||||||||||
2017 | |||||||||||||||||||||
Service revenues and sales | $ | 292,283 | $ | 136,074 | $ | - | $ | 428,357 | |||||||||||||
Cost of services provided and goods sold | 222,497 | 68,996 | - | 291,493 | |||||||||||||||||
Selling, general and administrative expenses (b) | 22,607 | 35,330 | 13,684 | 71,621 | |||||||||||||||||
Depreciation | 4,568 | 4,344 | 31 | 8,943 | |||||||||||||||||
Amortization | - | 26 | - | 26 | |||||||||||||||||
Other operating expense/(income) | (5,524 | ) | - | 5,266 | (258 | ) | |||||||||||||||
Total costs and expenses | 244,148 | 108,696 | 18,981 | 371,825 | |||||||||||||||||
Income/(loss) from operations | 48,135 | 27,378 | (18,981 | ) | 56,532 | ||||||||||||||||
Interest expense | (27 | ) | (65 | ) | (1,016 | ) | (1,108 | ) | |||||||||||||
Intercompany interest income/(expense) | 3,177 | 1,562 | (4,739 | ) | - | ||||||||||||||||
Other income/(expense)—net | (31 | ) | (64 | ) | 2,810 | 2,715 | |||||||||||||||
Income/(loss) before income taxes | 51,254 | 28,811 | (21,926 | ) | 58,139 | ||||||||||||||||
Income taxes (b) | (8,406 | ) | (3,228 | ) | 8,047 | (3,587 | ) | ||||||||||||||
Net income/(loss) | $ | 42,848 | $ | 25,583 | $ | (13,879 | ) | $ | 54,552 | ||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | |||||||||||||||||||||
FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017 | |||||||||||||||||||||
(in thousands)(unaudited) |
|||||||||||||||||||||
Chemed | |||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||
2018 | |||||||||||||||||||||
Service revenues and sales | $ | 1,197,562 | $ | 585,086 | $ | - | $ | 1,782,648 | |||||||||||||
Cost of services provided and goods sold | 929,306 | 299,338 | - | 1,228,644 | |||||||||||||||||
Selling, general and administrative expenses (a) | 80,969 | 145,683 | 43,557 | 270,209 | |||||||||||||||||
Depreciation | 19,688 | 18,629 | 147 | 38,464 | |||||||||||||||||
Amortization | 12 | 387 | - | 399 | |||||||||||||||||
Other operating expenses | 1,130 | 170 | - | 1,300 | |||||||||||||||||
Total costs and expenses | 1,031,105 | 464,207 | 43,704 | 1,539,016 | |||||||||||||||||
Income/(loss) from operations | 166,457 | 120,879 | (43,704 | ) | 243,632 | ||||||||||||||||
Interest expense | (175 | ) | (319 | ) | (4,496 | ) | (4,990 | ) | |||||||||||||
Intercompany interest income/(expense) | 12,832 | 6,908 | (19,740 | ) | - | ||||||||||||||||
Other income—net | 579 | 93 | 286 | 958 | |||||||||||||||||
Income/(loss) before income taxes | 179,693 | 127,561 | (67,654 | ) | 239,600 | ||||||||||||||||
Income taxes (a) | (40,847 | ) | (28,850 | ) | 35,641 | (34,056 | ) | ||||||||||||||
Net income/(loss) | $ | 138,846 | $ | 98,711 | $ | (32,013 | ) | $ | 205,544 | ||||||||||||
2017 | |||||||||||||||||||||
Service revenues and sales | $ | 1,148,260 | $ | 518,464 | $ | - | $ | 1,666,724 | |||||||||||||
Cost of services provided and goods sold | 886,062 | 264,470 | - | 1,150,532 | |||||||||||||||||
Selling, general and administrative expenses (b) | 95,215 | 136,248 | 45,189 | 276,652 | |||||||||||||||||
Depreciation | 18,616 | 16,667 | 205 | 35,488 | |||||||||||||||||
Amortization | 14 | 123 | - | 137 | |||||||||||||||||
Other operating expenses | 85,614 | - | 5,266 | 90,880 | |||||||||||||||||
Total costs and expenses | 1,085,521 | 417,508 | 50,660 | 1,553,689 | |||||||||||||||||
Income/(loss) from operations | 62,739 | 100,956 | (50,660 | ) | 113,035 | ||||||||||||||||
Interest expense | (188 | ) | (323 | ) | (3,761 | ) | (4,272 | ) | |||||||||||||
Intercompany interest income/(expense) | 11,656 | 5,596 | (17,252 | ) | - | ||||||||||||||||
Other income/(expense)—net | (126 | ) | (148 | ) | 8,428 | 8,154 | |||||||||||||||
Income/(loss) before income taxes | 74,081 | 106,081 | (63,245 | ) | 116,917 | ||||||||||||||||
Income taxes (b) | (16,436 | ) | (32,782 | ) | 30,478 | (18,740 | ) | ||||||||||||||
Net income/(loss) | $ | 57,645 | $ | 73,299 | $ | (32,767 | ) | $ | 98,177 | ||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||
FOR THE THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017 | ||||||||||||||||||||||
(in thousands)(unaudited) |
||||||||||||||||||||||
Chemed | ||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||
2018 | ||||||||||||||||||||||
Net income/(loss) | $ | 39,126 | $ | 25,911 | $ | (10,709 | ) | $ | 54,328 | |||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Interest expense | 22 | 64 | 1,091 | 1,177 | ||||||||||||||||||
Income taxes | 9,860 | 6,375 | (7,757 | ) | 8,478 | |||||||||||||||||
Depreciation | 4,935 | 4,847 | 40 | 9,822 | ||||||||||||||||||
Amortization | 12 | 291 | - | 303 | ||||||||||||||||||
EBITDA | 53,955 | 37,488 | (17,335 | ) | 74,108 | |||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Intercompany interest expense/(income) | (3,308 | ) | (1,678 | ) | 4,986 | - | ||||||||||||||||
Medicare cap sequestration adjustment | 456 | - | - | 456 | ||||||||||||||||||
Acquisition expense | 32 | 371 | - | 403 | ||||||||||||||||||
Litigation settlement costs | 1,000 | - | - | 1,000 | ||||||||||||||||||
Interest income | (111 | ) | (32 | ) | - | (143 | ) | |||||||||||||||
Stock option expense |
- | - | 3,251 | 3,251 | ||||||||||||||||||
Long-term incentive compensation | - | - | 2,242 | 2,242 | ||||||||||||||||||
Adjusted EBITDA | $ | 52,024 | $ | 36,149 | $ | (6,856 | ) | $ | 81,317 | |||||||||||||
2017 | ||||||||||||||||||||||
Net income/(loss) | $ | 42,848 | $ | 25,583 | $ | (13,879 | ) | $ | 54,552 | |||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Interest expense | 27 | 65 | 1,016 | 1,108 | ||||||||||||||||||
Income taxes | 8,406 | 3,228 | (8,047 | ) | 3,587 | |||||||||||||||||
Depreciation | 4,568 | 4,344 | 31 | 8,943 | ||||||||||||||||||
Amortization | - | 26 | - | 26 | ||||||||||||||||||
EBITDA | 55,849 | 33,246 | (20,879 | ) | 68,216 | |||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Intercompany interest expense/(income) | (3,177 | ) | (1,562 | ) | 4,739 | - | ||||||||||||||||
Interest income | (121 | ) | (10 | ) | - | (131 | ) | |||||||||||||||
Litigation settlement | (5,524 | ) | - | - | (5,524 | ) | ||||||||||||||||
Loss on sale of transportation equipment | - | - | 5,266 | 5,266 | ||||||||||||||||||
Medicare cap sequestration adjustment | 342 | - | - | 342 | ||||||||||||||||||
Expenses related to OIG investigation | 16 | - | - | 16 | ||||||||||||||||||
Amortization of stock awards | 71 | 66 | 160 | 297 | ||||||||||||||||||
Advertising cost adjustment | - | (664 | ) | - | (664 | ) | ||||||||||||||||
Stock option expense |
- | - | 2,747 | 2,747 | ||||||||||||||||||
Long-term incentive compensation | - | - | 1,973 | 1,973 | ||||||||||||||||||
Adjusted EBITDA | $ | 47,456 | $ | 31,076 | $ | (5,994 | ) | $ | 72,538 | |||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||
FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017 | ||||||||||||||||||||||
(in thousands)(unaudited) |
||||||||||||||||||||||
Chemed | ||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||
2018 | ||||||||||||||||||||||
Net income/(loss) | $ | 138,846 | $ | 98,711 | $ | (32,013 | ) | $ | 205,544 | |||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Interest expense | 175 | 319 | 4,496 | 4,990 | ||||||||||||||||||
Income taxes | 40,847 | 28,850 | (35,641 | ) | 34,056 | |||||||||||||||||
Depreciation | 19,688 | 18,629 | 147 | 38,464 | ||||||||||||||||||
Amortization | 12 | 387 | - | 399 | ||||||||||||||||||
EBITDA | 199,568 | 146,896 | (63,011 | ) | 283,453 | |||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Intercompany interest expense/(income) | (12,832 | ) | (6,908 | ) | 19,740 | - | ||||||||||||||||
Medicare cap sequestration adjustment | 1,496 | - | - | 1,496 | ||||||||||||||||||
Interest income | (580 | ) | (92 | ) | 1 | (671 | ) | |||||||||||||||
Accrued litigation settlement | 796 | - | - | 796 | ||||||||||||||||||
Acquisition Expense | 209 | 548 | - | 757 | ||||||||||||||||||
Amortization of stock awards | 107 | 100 | 239 | 446 | ||||||||||||||||||
Stock option expense | - | - | 12,611 | 12,611 | ||||||||||||||||||
Long-term incentive compensation | - | - | 6,618 | 6,618 | ||||||||||||||||||
Adjusted EBITDA | $ | 188,764 | $ | 140,544 | $ | (23,802 | ) | $ | 305,506 | |||||||||||||
2017 | ||||||||||||||||||||||
Net income/(loss) | $ | 57,645 | $ | 73,299 | $ | (32,767 | ) | $ | 98,177 | |||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Interest expense | 188 | 323 | 3,761 | 4,272 | ||||||||||||||||||
Income taxes | 16,436 | 32,782 | (30,478 | ) | 18,740 | |||||||||||||||||
Depreciation | 18,616 | 16,667 | 205 | 35,488 | ||||||||||||||||||
Amortization | 14 | 123 | - | 137 | ||||||||||||||||||
EBITDA | 92,899 | 123,194 | (59,279 | ) | 156,814 | |||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Intercompany interest expense/(income) | (11,656 | ) | (5,596 | ) | 17,252 | - | ||||||||||||||||
Interest income | (388 | ) | (39 | ) | - | (427 | ) | |||||||||||||||
Litigation settlement | 84,476 | 213 | - | 84,689 | ||||||||||||||||||
Medicare cap sequestration adjustment | 447 | - | - | 447 | ||||||||||||||||||
Loss on sale of transportation equipment | - | - | 5,266 | 5,266 | ||||||||||||||||||
Expenses related to OIG investigation | 5,194 | - | - | 5,194 | ||||||||||||||||||
Program closure expenses | 1,138 | - | - | 1,138 | ||||||||||||||||||
Amortization of stock awards | 291 | 269 | 670 | 1,230 | ||||||||||||||||||
Advertising cost adjustment | - | (1,371 | ) | - | (1,371 | ) | ||||||||||||||||
Stock option expense | - | - | 10,485 | 10,485 | ||||||||||||||||||
Long-term incentive compensation | - | - | 4,994 | 4,994 | ||||||||||||||||||
Adjusted EBITDA | $ | 172,401 | $ | 116,670 | $ | (20,612 | ) | $ | 268,459 | |||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||
RECONCILIATION OF ADJUSTED NET INCOME | |||||||||||||||||||||||
(in thousands, except per share data)(unaudited) |
|||||||||||||||||||||||
Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||||||||
Net income as reported | $ | 54,328 | $ | 54,552 | $ | 205,544 | $ | 98,177 | |||||||||||||||
Add/(deduct) pre-tax cost of: | |||||||||||||||||||||||
Stock option expense | 3,251 | 2,747 | 12,611 | 10,485 | |||||||||||||||||||
Long-term incentive compensation | 2,242 | 1,973 | 6,618 | 4,994 | |||||||||||||||||||
Litigation settlement | 1,000 | (5,524 | ) | 796 | 84,689 | ||||||||||||||||||
Medicare cap sequestration adjustments | 456 | 342 | 1,496 | 447 | |||||||||||||||||||
Acquisition expenses | 403 | - | 757 | - | |||||||||||||||||||
Loss on sale of transportation equipment | - | 5,266 | - | 5,266 | |||||||||||||||||||
Expenses of OIG investigation | - | 16 | - | 5,194 | |||||||||||||||||||
Program closure expenses | - | - | - | 1,138 | |||||||||||||||||||
Add/(deduct) tax impacts: | |||||||||||||||||||||||
Tax impact of the above pre-tax adjustments (1) | (1,527 | ) | (1,379 | ) | (4,586 | ) | (42,102 | ) | |||||||||||||||
Impact of tax reform | - | (8,302 | ) | - | (8,302 | ) | |||||||||||||||||
Excess tax benefits on stock compensation | (4,244 | ) | (10,811 | ) | (22,862 | ) | (18,932 | ) | |||||||||||||||
Adjusted net income |
$ |
55,909 |
$ |
38,880 |
$ |
200,374 |
$ | 141,054 | |||||||||||||||
Diluted Earnings Per Share As Reported | |||||||||||||||||||||||
Net income | $ | 3.26 | $ | 3.25 | $ | 12.23 | $ | 5.86 | |||||||||||||||
Average number of shares outstanding | 16,670 | 16,776 | 16,803 | 16,742 | |||||||||||||||||||
Adjusted Diluted Earnings Per Share | |||||||||||||||||||||||
Adjusted net income | $ | 3.35 | $ | 2.32 | $ | 11.93 | $ | 8.43 | |||||||||||||||
Average number of shares outstanding | 16,670 | 16,776 | 16,803 | 16,742 | |||||||||||||||||||
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||||||||||
OPERATING STATISTICS FOR VITAS SEGMENT | |||||||||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||||||||
Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||||||||||
OPERATING STATISTICS | 2018 | 2017 | 2018 | 2017 | |||||||||||||||||||||||||||
Net revenue ($000) (c) | |||||||||||||||||||||||||||||||
Homecare | $ | 261,972 | $ | 242,554 | $ | 1,010,518 | $ | 935,913 | |||||||||||||||||||||||
Inpatient | 20,874 | 22,033 | 82,677 | 90,472 | |||||||||||||||||||||||||||
Continuous care | 30,834 | 30,131 | 122,498 | 124,557 | |||||||||||||||||||||||||||
Other | 1,986 | - | 7,831 | - | |||||||||||||||||||||||||||
Subtotal | $ | 315,666 | $ | 294,718 | $ | 1,223,524 | $ | 1,150,942 | |||||||||||||||||||||||
Room and board, net | (2,191 | ) | - | (10,054 | ) | - | |||||||||||||||||||||||||
Contractual allowances | (3,036 | ) | - | (11,785 | ) | - | |||||||||||||||||||||||||
Medicare cap allowance | (3,454 | ) | (2,435 | ) | (4,123 | ) | (2,682 | ) | |||||||||||||||||||||||
Net Revenue | $ | 306,985 | $ | 292,283 | $ | 1,197,562 | $ | 1,148,260 | |||||||||||||||||||||||
Net revenue as a percent of total before Medicare cap allowance | |||||||||||||||||||||||||||||||
Homecare | 83.0 | % | 82.3 | % | 82.6 | % | 81.2 | % | |||||||||||||||||||||||
Inpatient | 6.6 | 7.5 | 6.8 | 7.9 | |||||||||||||||||||||||||||
Continuous care | 9.8 | 10.2 | 10.0 | 10.9 | |||||||||||||||||||||||||||
Other | 0.6 | - | 0.6 | - | |||||||||||||||||||||||||||
Subtotal | 100.0 | 100.0 | 100.0 | 100.0 | |||||||||||||||||||||||||||
Room and board, net | (0.7 | ) | - | (0.8 | ) | - | |||||||||||||||||||||||||
Contractual allowances | (1.0 | ) | - | (1.1 | ) | - | |||||||||||||||||||||||||
Medicare cap allowance | (1.1 | ) | (0.8 | ) | (0.2 | ) | (0.2 | ) | |||||||||||||||||||||||
Net Revenue | 97.2 | % | 99.2 | % | 97.9 | % | 99.8 | % | |||||||||||||||||||||||
Average daily census ("ADC") (days) | |||||||||||||||||||||||||||||||
Homecare | 14,062 | 12,861 | 13,652 | 12,549 | |||||||||||||||||||||||||||
Nursing home | 3,297 | 3,265 | 3,298 | 3,177 | |||||||||||||||||||||||||||
Routine homecare | 17,359 | 16,126 | 16,950 | 15,726 | |||||||||||||||||||||||||||
Inpatient | 326 | 342 | 327 | 354 | |||||||||||||||||||||||||||
Continuous care | 464 | 452 | 465 | 470 | |||||||||||||||||||||||||||
Total | 18,149 | 16,920 | 17,742 | 16,550 | |||||||||||||||||||||||||||
Total Admissions | 16,579 | 16,575 | 68,119 | 66,449 | |||||||||||||||||||||||||||
Total Discharges | 16,623 | 16,553 | 66,868 | 65,637 | |||||||||||||||||||||||||||
Average length of stay (days) | 92.6 | 91.4 | 89.9 | 88.8 | |||||||||||||||||||||||||||
Median length of stay (days) | 17.0 | 16.0 | 17.0 | 16.0 | |||||||||||||||||||||||||||
ADC by major diagnosis | |||||||||||||||||||||||||||||||
Cerebro | 35.8 | % | 36.1 | % | 36.3 | % | 35.5 | % | |||||||||||||||||||||||
Neurological | 18.6 | 18.5 | 19.0 | 19.2 | |||||||||||||||||||||||||||
Cancer | 13.7 | 14.1 | 13.7 | 14.6 | |||||||||||||||||||||||||||
Cardio | 16.3 | 16.4 | 16.4 | 16.5 | |||||||||||||||||||||||||||
Respiratory | 8.0 | 8.0 | 8.2 | 7.9 | |||||||||||||||||||||||||||
Other | 7.6 | 6.9 | 6.4 | 6.3 | |||||||||||||||||||||||||||
Total | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||||||||||
Admissions by major diagnosis | |||||||||||||||||||||||||||||||
Cerebro | 20.9 | % | 22.3 | % | 21.8 | % | 22.0 | % | |||||||||||||||||||||||
Neurological | 11.5 | 10.7 | 11.4 | 10.6 | |||||||||||||||||||||||||||
Cancer | 31.1 | 30.0 | 30.2 | 30.6 | |||||||||||||||||||||||||||
Cardio | 14.6 | 14.9 | 15.4 | 15.0 | |||||||||||||||||||||||||||
Respiratory | 10.1 | 10.7 | 10.9 | 10.8 | |||||||||||||||||||||||||||
Other | 11.8 | 11.4 | 10.3 | 11.0 | |||||||||||||||||||||||||||
Total | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||||||||||
Direct patient care margins (d) | |||||||||||||||||||||||||||||||
Routine homecare | 53.9 | % | 53.9 | % | 53.0 | % | 52.6 | % | |||||||||||||||||||||||
Inpatient | 3.9 | 8.5 | 4.7 | 5.4 | |||||||||||||||||||||||||||
Continuous care | 18.4 | 16.8 | 17.7 | 16.9 | |||||||||||||||||||||||||||
Homecare margin drivers (dollars per patient day) | |||||||||||||||||||||||||||||||
Labor costs | $ | 56.82 | $ | 55.65 | $ | 57.59 | $ | 56.80 | |||||||||||||||||||||||
Combined drug, home medical equipment and medical supplies cost |
13.58 | 14.30 | 14.06 | 14.65 | |||||||||||||||||||||||||||
Inpatient margin drivers (dollars per patient day) | |||||||||||||||||||||||||||||||
Labor costs | $ | 379.17 | $ | 355.96 | $ | 376.53 | $ | 366.41 | |||||||||||||||||||||||
Continuous care margin drivers (dollars per patient day) | |||||||||||||||||||||||||||||||
Labor costs | $ | 571.18 | $ | 583.45 | $ | 575.36 | $ | 584.49 | |||||||||||||||||||||||
Bad debt expense as a percent of revenues | 1.0 | % | 1.1 | % | 1.0 | % | 1.1 | % | |||||||||||||||||||||||
Accounts receivable -- | |||||||||||||||||||||||||||||||
Days of revenue outstanding- excluding unapplied Medicare payments | 35.0 | 33.7 | n.a. | n.a. | |||||||||||||||||||||||||||
Days of revenue outstanding- including unapplied Medicare payments | 24.6 | 25.0 |
n.a. |
n.a. |
|||||||||||||||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||||
FOOTNOTES TO FINANCIAL STATEMENTS | |||||||||||||||||||||||||
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2018 AND 2017 | |||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||
(a) | Included in the results of operations for 2018 are the following significant credits/(charges) which may not be indicative of ongoing operations | ||||||||||||||||||||||||
(in thousands): | |||||||||||||||||||||||||
Three Months Ended December 31, 2018 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||
Medicare cap sequestration adjustment | $ | (456 | ) | $ | - | $ | - | $ | (456 | ) | |||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Litigation settlement | (1,000 | ) | - | - | (1,000 | ) | |||||||||||||||||||
Acquisition expense | (32 | ) | (371 | ) | - | (403 | ) | ||||||||||||||||||
Stock option expense | - | - | (3,251 | ) | (3,251 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (2,242 | ) | (2,242 | ) | |||||||||||||||||||
Pretax impact on earnings | (1,488 | ) | (371 | ) | (5,493 | ) | (7,352 | ) | |||||||||||||||||
Excess tax benefits on stock compensation | - | - | 4,244 | 4,244 | |||||||||||||||||||||
Income tax benefit on the above | 381 | 98 | 1,048 | 1,527 | |||||||||||||||||||||
After-tax impact on earnings | $ | (1,107 | ) | $ | (273 | ) | $ | (201 | ) | $ | (1,581 | ) | |||||||||||||
For the Year Ended December 31, 2018 | |||||||||||||||||||||||||
VITAS |
Roto-Rooter |
Corporate | Consolidated | ||||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||
Medicare cap sequestration adjustment | $ | (1,496 | ) | $ | - | $ | - | $ | (1,496 | ) | |||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Litigation settlement | (796 | ) | - | - | (796 | ) | |||||||||||||||||||
Acquisition expense | (209 | ) | (548 | ) | - | (757 | ) | ||||||||||||||||||
Stock option expense | - | - | (12,611 | ) | (12,611 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (6,618 | ) | (6,618 | ) | |||||||||||||||||||
Pretax impact on earnings | (2,501 | ) | (548 | ) | (19,229 | ) | (22,278 | ) | |||||||||||||||||
Excess tax benefits on stock compensation | - | - | 22,862 | 22,862 | |||||||||||||||||||||
Income tax benefit on the above | 637 | 145 | 3,804 | 4,586 | |||||||||||||||||||||
After-tax impact on earnings | $ | (1,864 | ) | $ | (403 | ) | $ | 7,437 | $ | 5,170 | |||||||||||||||
(b) | Included in the results of operations for 2017 are the following significant credits/(charges) which may not be indicative of ongoing operations | ||||||||||||||||||||||||
(in thousands): | |||||||||||||||||||||||||
Three Months Ended December 31, 2017 | |||||||||||||||||||||||||
VITAS |
Roto-Rooter |
Corporate | Consolidated | ||||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||
Medicare cap sequestration adjustment | $ | (342 | ) | $ | - | $ | - | $ | (342 | ) | |||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Expenses related to OIG investigation | (16 | ) | - | - | (16 | ) | |||||||||||||||||||
Stock option expense | - | - | (2,747 | ) | (2,747 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (1,973 | ) | (1,973 | ) | |||||||||||||||||||
Other operating expenses: | |||||||||||||||||||||||||
Litigation settlements | 5,524 | - | - | 5,524 | |||||||||||||||||||||
Loss on sale of transportation equipment | - | - | (5,266 | ) | (5,266 | ) | |||||||||||||||||||
Pretax impact on earnings | 5,166 | - | (9,986 | ) | (4,820 | ) | |||||||||||||||||||
Impact of tax reform | 11,057 | 7,761 | (10,516 | ) | 8,302 | ||||||||||||||||||||
Excess tax benefits on stock compensation | - | - | 10,811 | 10,811 | |||||||||||||||||||||
Income tax benefit on the above | (1,961 | ) | - | 3,340 | 1,379 | ||||||||||||||||||||
After-tax impact on earnings | $ | 14,262 | $ | 7,761 | $ | (6,351 | ) | $ | 15,672 | ||||||||||||||||
For the Year Ended December 31, 2017 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||
Medicare cap sequestration adjustment | $ | (447 | ) | $ | - | $ | - | $ | (447 | ) | |||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Expenses related to OIG investigation | (5,194 | ) | - | - | (5,194 | ) | |||||||||||||||||||
Litigation settlement | - | (213 | ) | - | (213 | ) | |||||||||||||||||||
Stock option expense | - | - | (10,485 | ) | (10,485 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (4,994 | ) | (4,994 | ) | |||||||||||||||||||
Other operating expenses: | |||||||||||||||||||||||||
Litigation settlement | (84,476 | ) | - | - | (84,476 | ) | |||||||||||||||||||
Loss on sale of transportation equipment | - | - | (5,266 | ) | (5,266 | ) | |||||||||||||||||||
Program closure expenses | (1,138 | ) | - | - | (1,138 | ) | |||||||||||||||||||
Pretax impact on earnings | (91,255 | ) | (213 | ) | (20,745 | ) | (112,213 | ) | |||||||||||||||||
Impact of tax reform | 11,057 | 7,761 | (10,516 | ) | 8,302 | ||||||||||||||||||||
Excess tax benefits on stock compensation | - | - | 18,932 | 18,932 | |||||||||||||||||||||
Income tax benefit on the above | 34,722 | 84 | 7,296 | 42,102 | |||||||||||||||||||||
After-tax impact on earnings | $ | (45,476 | ) | $ | 7,632 | $ | (5,033 | ) | $ | (42,877 | ) | ||||||||||||||
(c) |
VITAS has 11 large (greater than 450 ADC), 18 medium (greater than 200 but less than 450 ADC) and 18 small (less than 200 ADC) hospice programs. Of VITAS' 30 Medicare provider numbers, 25 provider numbers have a Medicare cap cushion of 10% or greater during the current cap year, one provider number has a Medicare cap cushion between 5% and 10%, two provider numbers have a Medicare cap cushion between 0% and 5%, and two provider numbers would have a Medicare cap liability. |
|
(d) | Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation. | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005861/en/
Source:
David P. Williams
(513) 762-6901